Heterogeneity, urgency, generalizability, and enrollment: The HUGE balance in ALS trials

TY - JOUR

T1 - Heterogeneity, urgency, generalizability, and enrollment

T2 - The HUGE balance in ALS trials

AU - Karam, Chafic

AU - Berry, James D.

N1 - Funding Information: C. Karam serves on a Data Safety Monitoring Board for a Phase 2/3 Trial of Arimoclomol in Inclusion Body Myositis (IBM); has received speaker honoraria from Akcea, Alnylam, Alexion, and CSL Behring; served on the editorial boards of the Neurology Resident and Fellow section and Disputes & Debates (letters to the editor) section; and has received consulting honoraria from Akcea, Alnylam, Alexion, Biogen, Cytokinetics, Genzyme, and CSL Behring. J. Berry has served on scientific advisory boards for MT Pharma, Denali Therapeutics, Orion Corporation, Anelixis Therapeutics, and Mayo Clinic; has received travel funding from the ALS Association, Muscular Dystrophy Association, ALS One, and ALS Finding a Cure; holds a patent for MicroRNAs in neurodegenerative disorders (WO2013055865); has received research support from Voyager Therapeutics, Neuraltus Pharmaceuticals, Cytokinetics, Brainstorm Cell Therapeutics, Amylyx Pharmaceuticals, NIH, Muscular Dystrophy Association, ALS Finding a Cure, ALS Association, and ALS One; and receives licensing royalty payments for the aforementioned patent. In addition, his wife is an editorial board member of Neuro-psychopharmacology. Go to Neurology.org/N for full disclosures. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/1/29

Y1 - 2019/1/29

UR - http://www.scopus.com/inward/record.url?scp=85064443537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064443537&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000006837

DO - 10.1212/WNL.0000000000006837

M3 - Editorial

AN - SCOPUS:85064443537

VL - 92

SP - 215

EP - 216

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -